chrisvoncsefalvay/vaers-outcomes huggingface dataset:
1st dose in 2020, no 2nd dose yet; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received first dose in July 2020).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK receipt date: 23-Nov-2022 Reporter's comment: The pharmacist called to request information on how to proceed with the vaccination of a patient who wanted to receive the second dose to complete the scheme. The reporter agreed to follow-up by safety team.  More details of the event were unknown to the reporter since the patient received the first dose in another facility. The reporter consented to follow-up. Additional supportive information: Till the time of reporting, the patient did not receive second dose of Shingrix, which led to incomplete course of vaccination.
2/9 NEXT DAY IN AM 99.7 FEVER; SORE ARM MUSCLE TO MOVE ARM.   2/10 DAY TWO 48 HRS  3-6:00PM TIGHT BURNING CENTER CHEST PAIN TOOK TYLENOL; WATER.   2/11 DAY 3 - TIGHT BURNING CHEST PAIN INTERMITTENT ALL DAY - TOOK TYLENOL; HYDRATED WITH WATER.   2/12 DAY 4 - NO DISCOMFORT; GOT COVID TEST TO RULE OUT - NEGATIVE.   2/13 DAY 5 TIGHT CHEST PAIN 1:00PM TOOK TYLENOL SUBSIDED ONE HOUR. 8:00PM BLOODY NOSE 30 MINUTES.   OK THERE AFTER.
I received the first three injections of Anthrax on 28 June 1999, 12 July 1999, and 26 July 1999.  I noticed after I got the shots that I started getting dry skin on my right hand and small fluid filled blisters on one finger that also developed over time.  My skin on two fingers of my right hand also cracked and peeled progressively. It became worse.  It is now covering my both hands and both ankles.  I have tried treatment of all kinds and nothing has worked.  I believe my skin problems are related to me receiving the anthrax shots.  Although I did not catch the skin version of the anthrax, it still affected my skin by causing these problems.
Hand was hurting really bad; neck hurting; feet hurting; knee hurting; Nausea; Severe joint pain; slight headache; tired; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (Hand was hurting really bad), NECK PAIN (neck hurting), PAIN IN EXTREMITY (feet hurting), HEADACHE (slight headache) and FATIGUE (tired) in a 64-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 011L20A and 012L20A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concomitant products included RALOXIFENE HYDROCHLORIDE (EVISTA) from 2006 to an unknown date.   On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 11-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 14-Jan-2021, the patient experienced HEADACHE (slight headache) and FATIGUE (tired). On 19-Jan-2021, the patient experienced ARTHRALGIA (Severe joint pain). On 12-Feb-2021, the patient experienced NAUSEA (Nausea). On an unknown date, the patient experienced PAIN IN EXTREMITY (Hand was hurting really bad), NECK PAIN (neck hurting), PAIN IN EXTREMITY (feet hurting) and ARTHRALGIA (knee hurting). The patient was treated with DICLOFENAC SODIUM (VOLTARENE [DICLOFENAC SODIUM]) at an unspecified dose and frequency and Surgery ( right shoulder surgery over 10 years ago without any known sequelae) for Arthralgia. On 26-Jan-2021, ARTHRALGIA (Severe joint pain) had resolved. At the time of the report, PAIN IN EXTREMITY (Hand was hurting really bad), NECK PAIN (neck hurting), PAIN IN EXTREMITY (feet hurting), HEADACHE (slight headache), FATIGUE (tired) and ARTHRALGIA (knee hurting) outcome was unknown and NAUSEA (Nausea) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Evista concomitant drug used for indication of bone health.   This case was linked to MOD-2021-089653, MOD-2021-089653 (Patient Link).   Most recent FOLLOW-UP information incorporated above includes: On 04-Feb-2021: Follow up received on 04-FEB-2021 included new events, concomitant medication.
12 hours post vaccination patient experienced severe chills and nausea that resolved at 24 hours post vaccination. Patient also noticed several days later a small rash near axilla that appeared like small, red dots. it was approximately 2 inches in diameter and was not raised, blistering  or causing any discomfort.
Local swelling, erythema over (L) thigh around area of vaccine about 30 cm in diameter. Began 2/8/13. Per Dad started 2/8/13 and has gotten larger.
neuralgia pain; severe case of shingles / not resolved; This case was reported by a pharmacist via call center representative and described the occurrence of shingles in a 69-year-old female patient who received Herpes zoster (Shingrix) (batch number B93K4, expiry date 7th May 2022) for prophylaxis.   On 18th November 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. In November 2020, less than a week after receiving Shingrix, the patient experienced shingles. On 2nd December 2020, the patient experienced neuralgia. On an unknown date, the outcome of the shingles and neuralgia were not recovered/not resolved.   It was unknown if the reporter considered the shingles and neuralgia to be related to Shingrix.  Additional information was provided as follows: The patient received 1st dose of Shingrix and developed a severe case of shingles. The pharmacist reported that, the patient had neuralgia pain and the prescription was picked up for the same. The reporter consented to follow up.
Headache, neck pain, skin tenderness, fatigue, irritability. I took Tylenol 1,000 mg followed by 600 mg of ibuprofen for the last 2 days.
Shingles after getting Shingrix vaccine two weeks ago; This case was reported by a consumer and described the occurrence of shingles in a 50-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   In January 2021, the patient received Shingrix. On an unknown date, less than 2 weeks after receiving Shingrix and an unknown time after starting Valacyclovir, the patient experienced shingles. The patient was treated with valaciclovir hydrochloride (Valacyclovir). On an unknown date, the outcome of the shingles was unknown.   It was unknown if the reporter considered the shingles to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had shingles after getting Shingrix vaccine two weeks ago. The primary care physician said that it rare and prescribed me Valacyclovir 1000 mg every 8 hours for 7 days.
Pfizer contacted, vaccine diluted incorrectly by mistake, patient contacted and reports no adverse reactions at this time
Emergency room really sick; This case was reported by a consumer via interactive digital media and described the occurrence of sickness in a patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, unknown after receiving Shingles vaccine, the patient experienced sickness. On an unknown date, the outcome of the sickness was unknown.   It was unknown if the reporter considered the sickness to be related to Shingles vaccine.  Additional details were provided as follows: The patient self reported this case. The age at vaccination was not reported. The patient reported that the shingles vaccine sent him/her to the emergency room, was really sick. The follow-up would not possible as no contact details were available.
Patient came in with mom for booster dose of Pfizer. They scheduled the appt online and it was no caught at time of vaccination that she was not yet at the 5 month mark after last dose for booster. Her last dose was 09/20/21.
Moderna COVID-19 Vaccine EUA: COVID-19 case resulting in Hospitalization/Death. Rec'd Moderna vaccine on 1/16/2021, 2/19/21 and 11/03/21. Presented to ED with c/o AMS. Recently d/c after being admitted for PNA and UTI. On arrival to ER: febrile & tachypneic in AFib w/RVR, improved with IV Cardizem. Workup in the ER revealed COVID positive, CT head and chest x-ray no acute findings. Placed on Airvo and HFNC. Cont'd to deteriorate despite aggressive care. Transitioned to inpatient hospice and expired on 9/20/22. TX'd w/cefepime, decadron, remdesivir, zosyn, ceftriaxone, and vancomycin.
allergic reaction; chills; dizziness; weakness; This is a spontaneous report from a contactable consumer (patient). A male patient of an unspecified age received BNT162b2 (Pfizer-BioNTech Covid-19 mRNA Vaccine, Solution for injection, Batch/Lot number and Expiration date was not reported) via an unspecified route of administration on 07Mar2021 as dose 1, single for COVID-19 immunisation. The patient medical history was not reported. There were no concomitant medications. On 08Mar2021, after 24 hours of the vaccination, patient experienced chills, dizziness and weakness. Patient stated that he thinks that he had an allergic reaction. Patient was going to contact his primary care physician. Patient stated that two days later the symptoms had disappeared. The outcome of all the events was recovered on 10Mar2021.   No follow-up attempts are possible; information about batch/ lot number cannot be obtained.
experienced a brief convulsion; This case was reported by a consumer via call center representative and described the occurrence of convulsion in a male patient who received Men B NVS (Meningococcal B vaccine) for prophylaxis.   On an unknown date, the patient received Meningococcal B vaccine. On an unknown date, less than a day after receiving Meningococcal B vaccine, the patient experienced convulsion (serious criteria GSK medically significant). On an unknown date, the outcome of the convulsion was unknown.   It was unknown if the reporter considered the convulsion to be related to Meningococcal B vaccine.  Additional details were provided as follows: The case was reported by the patient's parent. The age at vaccination was not reported. The reporter stated that, the patient received a Meningococcal B vaccine and after that experienced a brief convulsion at the doctor's office. No other contact details or patient details were reported. The reporter consented to follow up.
Pt recvd Hep B vax on 17JAN91 & 1 hr following inject pt exp chest pain & tightness, lt arm pain, & dyspnea; On 18JAN91 the pain persisted & pt was subsequently seen ER;
This spontaneous report as received from a register nurse, refers to an unspecified number of patients, of an unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patients were vaccinated with improperly stored ROTATEQ, oral, (strength, dosage and lot# were not reported). None symptoms were reported. This is one of several reports received from the same reporter. Additional information has been requested.
Patient received Prevnar 13 vaccine on 6/18/15 and reported back to clinicin on 6/23/15 with itching and urticaria around injection site of 2cm x4cm. Patient given corticosteriod cream.
Per history 24-36 hrs s/p injection, employee developed nodes in neck next day, nodes in arm pits, then groin. 3-4 days s/p inj. developed (R) wrist pain & STS and next day left knee pain and STS. Next day developed fever x 1 night. She saw her primary MD. All sx have resolved. All of above is given from employee Hx.
3/19/21  2:30 am   Fever lasting aprox 3 days 3/30/21  8:00 pm  100.5 Fever & aches lasting 4 hours 3/31/21  7:30 pm  101.1  Fever & aches lasting 4 hours 4/1/21     2:00 am    Fever & Aches with EXTREME chills lasting 1 hr. 4/1/21  Cold sores and cankars lasting 1 week 4/10/21 very mild cold
This spontaneous report was received from a medical assistant (clinical coordinator) and refers to a patient of unknown age and gender. No information regarding the patient's pertinent medical history, drug reactions or allergies and concomitant medications was provided. On an unknown date in 2017, between 27-JUL-2017 and 03-AUG-2017, the patient was vaccinated with improperly stored dose of VARIVAX injection (lot # reported as N008077; expiration date: 09-MAR-2019; dose and route of administration were not reported). Concomitant therapy included properly stored sterile diluent (MERCK) injection. The reporter stated that the administered dose of VARIVAX was stored at temperature of -10.7 degrees Celsius for 2 hours 10 minutes. Data logger was used to detect temperature excursions. There were no previous temperature excursions reported. No adverse effects were reported. No product quality complaint was involved. This is one of seven reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1708USA005837: US-009507513-1708USA005841: US-009507513-1708USA005839: US-009507513-1708USA003358: US-009507513-1708USA005836: US-009507513-1708USA005838.
This spontaneous report as derived from a newspaper article (02-DEC-2012) reported that according to a spokesman of the state Department of Health, an investigation into possible causes and contributing factors in a chickenpox outbreak is ongoing and will be for months. The patients were vaccinated with a chicken pox vaccine of Merck. No other co-suspects were reported. No concomitant medications were reported. In early October 2012, more than 100 patients experienced a chickenpox outbreak. the outbreak included 2 counties and an adjacent county in another state. With the exception of one city, this was primary a very rural area. The state and federal health official said that it did not appear that the outbreak was caused by a bad lot, or batch of the vaccine. There are numerous cases in elementary school children (age not provided), there have been 3 waves of cases, 2/3 of the cases had received 2 doses, but this was just a rough estimate. Not all cases are from one lot or one provider office. The reporter did not think there were any storage or handling issues with the vaccine. The index case was an unvaccinated child who attended school. Patients was vaccinated individual who subsequently developed a mild case of breakthrough disease (varicella) during the outbreak received multiple lots of chickenpox vaccine over several years. No treatment information was reported. The outcome of breakthrough disease chickenpox (varicella) was unknown. The relatedness for breakthrough disease chickenpox was not reported for varicella virus vaccine live (Merck). Additional information has been requested.
Sore arm after the first dose of COVID Vaccine; This is a spontaneous report from a contactable other health professional (Patient). A 64-years-old female patient received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Batch/lot number: EK57530), via an unspecified route of administration on 17Dec2020 09:10 at left arm, at single dose for covid-19 immunization. Medical history was none.  There were no concomitant medications. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient got the Flu Vaccine last part of Sep2020 or Beginning of Oct2020. The patient experienced sore arm after the first dose of covid vaccine on 17Dec2020. She received the first dose on 17Dec2020 and tolerated pretty well. She only had a sore arm. It started the same day on 17Dec2020, a couple of hours after getting the vaccine. It went away a day to a day and a half after it started. After that she was fine. the outcome of the event was recovered in Dec2020. Reporter considered the event Sore arm after the first dose of COVID Vaccine was not serious. Event did not result in Emergency Room/Physician Office. She also stated, even though she got so sick with getting the vaccine she was just continuously  telling her self this is better than having COVID. She stated she even told people even if she knew after getting the shot she would have this reaction she would still take it. She has seen death occur from COVID and does not want that to happen.
Within 1 minute of receiving vaccine patient fainted and fell from the chair onto the floor. She  regained consciousness within a few seconds.  She drank water and had  a snack and symptoms quickly improved.  Patient left on her own about 30 minutes after vaccine.  I spoke with patient approximately 3 hours later and she said she was feeling OK.
I got a rash of itchy small red bumps, mostly on my ribcage, starting the day after the vaccine and getting worse 2 days after the vaccine.
1 of 2 pts who exp an adverse event following vax; pt recv vax 16SEP94; 19SEP pt reported that had exp a low grade fever, irritability & DTAP site was red & swollen; site treated w/ice; APAP prescribed; pt recovered;
Tingling in left arm, blurred vision, severe stomach pains, headache, dizzy, weak, nausea, vomiting, fever, joint and muscle pain, feeling sick, sweating and shivering. Took Ibuprofen and stayed in bed.
Patient states she had mild fever that resolved the next day, however, arm was still hurting as of 11/1/2017 with limited range of motion in arm. Patient called pharmacy to ask if this was normal and to find out what to do. Pharmacist advised her to ice it and call physician.
Tel-com. with mother, pt had her PCV-13 on 2-9-11 at around 14:00. At 22:00 pt started with a high temp 103 degrees. Parent gave TYLENOL. The temp. came down with med but would return. On 2-10-11 parent said that pt would cry with movement adv. to go to ER.
no adverse reaction noted - MMRV was inadvertently administered instead of MMR because of how much the boxes look and sound alike.
This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Expired doses administered to multiple patients) and PRODUCT STORAGE ERROR (Total amount of time the vial was exposed to room temperature range (8 degree to 25 degree Centigrate equals to 46 degree to 77 degree Fahrenheit) was about 27 hours) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 049L21A) for COVID-19 vaccination. No Medical History information was reported.    In May 2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. In May 2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Expired doses administered to multiple patients). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Total amount of time the vial was exposed to room temperature range (8 degree to 25 degree Centigrate equals to 46 degree to 77 degree Fahrenheit) was about 27 hours). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Expired doses administered to multiple patients) and PRODUCT STORAGE ERROR (Total amount of time the vial was exposed to room temperature range (8 degree to 25 degree Centigrate equals to 46 degree to 77 degree Fahrenheit) was about 27 hours) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medication information was provided.  Patient received the booster dose.  The vial was punctured for more than 12 hours. The vial was initially stored in the refrigerator on 09-May-2022. The vial was first punctured on 23-May-2022 at 8:30 AM. The vial was stored post puncture at room temperature. The vial did not undergo any temperature excursions. The room is about 74F where the vaccine was stored in room temperature range.  No treatment information was reported.
Vaccine given 3 days ago - rash, itching around vaccination site - approximately 5" length/area from elbow up; "tight" feeling.
Following morning patient was "Foggy" in the brain and unable to string words together in a sentence very well.  He let me know he could not focus enough to read and retain anything.  He wanted to talk but couldn't find the words.  He remained very quiet but had no other symptoms of fever, pain, or anything else.  10 days post vaccine and he is doing better but still not feeling normal and not talking and holding conversations as usual.  He is able to answer appropriately .  The last two days he said all food is tasting bland without a lot of flavor.  He has taken a couple Tylenol  the last two days and drank Echinacea tea to try and make an improvement.  Is there data or information to give us any idea how long this could last?
administered Boostrix, but it had expired; This case was reported by a nurse via call center representative and described the occurrence of expired vaccine used in a 66-year-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number 43E4T, expiry date 1st October 2021) for prophylaxis.   Co-suspect products included dtpa vaccine. pre-filled syringe device (Boostrix Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 26th October 2021, the patient received Boostrix and Boostrix Pre-Filled Syringe Device. On 26th October 2021, unknown after receiving Boostrix and Boostrix Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.  Additional details were provided as follows: The patient received expired dose of Menveo, which led to expired vaccine used. The reporter consented to follow up.
Information has been received from a nurse concerning a 17 year old female who on an unspecified date "couple of weeks ago" was vaccinated with Gardasil (lot# unknown) injection.  Concomitant therapy included MENACTRA and Varivax (MSD) (lot# unknown).  The patient experienced syncope "1 or 2 minutes" after receiving the Gardasil vaccination.  Medical attention was sought.  The nurse had given the patient a Popsicle.  The patient had fully recovered and walked out of the office the same day as the vaccination.  Additional information has been requested.
In clinic reporting pain in left deltoid with swelling & redness. Pain located at injection site. Reports pain x 3 days.
For reporting purpose only. Pt was given KINRIX vaccine at 18 months of age. No problems noted on patient.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Physician). The reporter is the patient.  A 29-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 29 years for covid-19 immunisation; coviD-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "Migraines" (unspecified if ongoing); "Obesity" (unspecified if ongoing). Concomitant medication(s) included: TYLENOL; IBUPROFEN; SUDAFED [XYLOMETAZOLINE HYDROCHLORIDE]. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". Therapeutic measures were taken as a result of drug ineffective, covid-19.  Clinical course: vaccine received and other medication with in in 2weeks received. No Known allergies  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.; Sender's Comments: Based on the information provide and plausible temporal association, the causality between BNT162B2 and events cannot be completely excluded.
24 hours after receiving DTaP, IPV, MMR, Hep A and Influenza patient experience lip and left upper extremity swelling.